C4 Therapeutics, Inc. in July 2023 appointed Mary Christian, Pharm.D. joined C4T as senior vice president, regulatory with more than two decades of experience in regulatory and drug development.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.885 USD | +0.93% | -8.86% | -13.54% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.54% | 337M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory